Descrizione del progetto
Nuovi bersagli terapeutici per le malattie rare e i tumori
La via di segnalazione fosfoinositide 3-chinasi (PI3K) è una via fondamentale che regola la crescita cellulare, il metabolismo e la sopravvivenza. L’omologo della fosfatasi e della tensina (PTEN) funge da regolatore negativo della via e ricopre un ruolo antitumorale. L’obiettivo del progetto PIPgen, finanziato dall’UE, è sfruttare le conoscenze esistenti nell’ambito del coinvolgimento di PI3K/PTEN nel cancro per capire le ripercussioni della via in malattie rare monogeniche, tra cui le sindromi da iperaccrescimento, le immunodeficienze primarie e le carenze cognitive. Al contrario, le informazioni sulla PI3K nel campo delle patologie rare verranno utilizzate per i tumori. I risultati scientifici di base generati getteranno le basi per la progettazione di nuove terapie rivolte alle diverse malattie rare che colpiscono milioni di cittadini in tutta Europa.
Obiettivo
There are more than 7000 rare diseases, affecting approximately 30 million European Union citizens. Eighty percent of rare diseases have monogenic origin and are often chronic or life-threatening. Several of these genetic mutations are also implicated in cancer, a disease of epidemic proportions (>14 million new cases/year worldwide). Genetic alterations in the PI3K/PTEN pathway are common events in both monogenic rare diseases and in cancer. Despite the molecular commonalities, these two pathologies have predominantly been investigated as independent entities. We aim to take advantage of the knowledge that has been generated regarding the role of PI3K in cancer to better understand the recently-discovered PI3K-related rare diseases (overgrowth syndromes, primary immunodeficiencies and cognitive deficiencies). Conversely, discoveries emanating from PI3K-related rare diseases will impact in the understanding of cancer. Ultimately, this cross-fertilization will impact on the clinical strategies to treat both rare diseases and cancer. Our network, under the acronym of PIPgen, aims to (1) produce the next generation of scientists that can navigate with ease between academic, industrial and clinical sectors and have the scientific and softs skills to convert research findings into commercialization and clinical applications, and (2) generate innovative knowledge that can be translated to the diagnosis and treatment of both rare diseases and cancer. This network provides a pan-European interdisciplinary and intersectorial training program of excellence bringing young researchers together with world leading academics, clinicians, entrepreneurs with experience from the pharma industry, corporate research as well as with dissemination and outreach activities. PIPgen has been conceived to make a real therapeutic impact both in rare diseases and cancer, based on basic bioscience.
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Meccanismo di finanziamento
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinatore
08916 Badalona
Spagna